RSS | Login | Register

CEFTIN

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare CEFTIN to:

Generic Name for CEFTIN

Cefuroxime (as axetil) 250mg, 500mg; tabs.

Legal Classification:

Pharmacological Class for CEFTIN

Cephalosporin.

Manufacturer of CEFTIN

GlaxoSmithKline Pharmaceuticals

Indications for CEFTIN

Susceptible mild to moderate infections including pharyngitis/tonsillitis, acute maxillary sinusitis, bronchitis, acute otitis media; uncomplicated skin and skin structure, UTIs, gonorrhea; early Lyme disease.

Adult dose for CEFTIN

≥13 years: Pharyngitis/tonsillitis, sinusitis: 250mg twice daily for 10 days. Acute bacterial exacerbations of chronic bronchitis, skin and skin structure infections: 250–500mg twice daily for 10 days. Secondary bacterial infections of acute bronchitis: 250–500mg twice daily for 5–10 days. UTIs: 250mg twice daily for 7–10 days. Gonorrhea: 1g as a single dose. Lyme disease: 500mg twice daily for 20 days.

Children's dosing for CEFTIN

Swallow tab whole, or use susp. Otitis media, sinusitis: 250mg twice daily for 10 days.

Also:

CEFTIN ORAL SUSPENSION

Precautions for CEFTIN

Tabs and susp not bioequivalent; do not interchange on a mg/mg basis. Penicillin or other allergy. History of colitis; discontinue if colitis occurs and treat. Renal impairment. Monitor prothrombin time in renal or hepatic dysfunction, stabilized on anticoagulant, poor nutritional state, or long-term use. Labor & delivery. Pregnancy (Cat.B). Nursing mothers: consider discontinuing nursing during treatment.

Interactions for CEFTIN

May cause false (+) Fehling's or Benedict's soln, Clinitest, or Coomb's test. Antacids, others that decrease gastric acidity may inhibit absorption. Potentiated by probenecid. Caution with potent diuretics, other nephrotoxic drugs.

Adverse Reactions for CEFTIN

GI disturbances, transient increase of AST, ALT, LDH, eosinophilia, bitter taste; convulsions (overdose).

How is CEFTIN supplied?

Tabs—20, 60
Susp 125mg/5mL—100mL
Susp 250mg/5mL—50mL, 100mL

Related Disease:

Infections, bacterial~systemic antiinfectives

Sinusitis

Cayston inhaled antibiotic approved for cystic fibrosis

February 23, 2010

The FDA has approved Cayston (aztreonam for inhalation solution, from Gilead Sciences) as a treatment to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa.

Phase 3 study of fidaxomicin for clostridium difficile infection (CDI)

February 05, 2010

Optimer Pharmaceuticals announced positive top-line results from the second of two Phase 3 trials evaluating the safety and efficacy of fidaxomicin (OPT-80) in patients with Clostridium difficile Infection (CDI).

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Phase 2 study of Arikace for treatment of pseudomonas lung infections

October 19, 2009

Transave reported additional positive clinical trial results on its lead investigational drug, Arikace (liposomal amikacin for inhalation), an antibiotic to treat chronic lung infections.